Abstracts tagged "pediatric rheumatology and juvenile idiopathic arthritis (JIA)"

Abstract Number: 431 • 2019 ACR/ARP Annual Meeting
Psychometric Properties of the Pediatric Patient-Reported Outcomes Measurement Information System (PROMIS®) Item Banks in a Dutch Clinical Sample of Children with Juvenile Idiopathic Arthritis
Michiel Luijten ¹, Caroline Terwee ², Hedy van Oers ², Mala Joosten ³, Merlijn van den Berg ², Dieneke Schonenberg-Meinema ², Koert Dolman ⁴, Rebecca Ten Cate ⁵, Leo Roorda ⁶, Martha Grootenhuis ³, Marion van Rossum⁷ and Lotte Haverman ², ¹Amsterdam University Medical Centers, Amsterdam, Noord-Holland, Netherlands, ²Amsterdam University Medical Centers, Amsterdam, Netherlands, ³Princess Maxima Centre for Pediatric Oncology, Utrecht, Netherlands, ⁴Onze Lieve Vrouwe Gasthuis West, Amsterdam, Netherlands, ⁵Leiden University Medical Centre, Leiden, Netherlands, ⁶Amsterdam Rehabilitation Research Center | Reade, Amsterdam, Netherlands, ⁷Amsterdam University Medical Centers, Amsterdam
Background/Purpose: Patient-reported outcome measures (PROMs) are often used to include the patients perspective on treatment (outcome). However, the choice of PROMs is difficult, as there…
Abstract Number: 1815 • 2019 ACR/ARP Annual Meeting
Subcutaneous or Intravenous Abatacept Monotherapy in Pediatric Patients with Polyarticular-Course JIA: Results from Two Phase III Trials
Nicolino Ruperto¹, Daniel J. Lovell ², John Bohnsack ³, Johannes Breedt ⁴, Michel Fischbach ⁵, Thomas Lutz ⁶, Kirsten Minden ⁷, Tatiana Miraval ⁸, Mahmood M. T. M. Ally ⁹, Nadina Rubio-Pérez ¹⁰, Elisabeth Gervais ¹¹, Riana van Zyl ¹², Robert Wong ¹³, Marleen Nys ¹⁴, Alberto Martini ¹⁵ and Hermine Brunner ¹⁶, ¹Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ²Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, ³University of Utah School of Medicine, Salt Lake City, UT, ⁴Steve Biko Academic Hospital, University of Pretoria, Pretoria, South Africa, ⁵Pédiatrie 1, CHU Hautepierre, Strasbourg, France, ⁶Heidelberg University Hospital, Heidelberg, Germany, ⁷German Rheumatism Research Center and Charité University Medicine, Berlin, Germany, ⁸Clínica San Gabriel, Lima, Peru, ⁹University of Pretoria, Pretoria, South Africa, ¹⁰University Hospital Dr. José Eleuterio González, Monterrey, Mexico, ¹¹CHU de Poitiers, Rheumatology, Poitiers, France, ¹²University of the Free State, Bloemfontein, South Africa, ¹³Bristol-Myers Squibb, Princeton, ¹⁴Bristol-Myers Squibb, Braine L’Alleud, Belgium, ¹⁵IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy, ¹⁶Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: In EU, abatacept (ABA) with MTX is approved in patients (pts) with polyarticular-course JIA (pJIA), as young as 2 years (SC) and 6 years…
Abstract Number: 2708 • 2019 ACR/ARP Annual Meeting
Effect of Immunogenicity on Efficacy and Safety of Subcutaneous or Intravenous Abatacept in Pediatric Patients with Polyarticular-Course JIA: Findings from Two Phase III Trials
Hermine Brunner¹, Nikolay Tzaribachev ², Ingrid Louw ³, Alberto Berman ⁴, Inmaculada Calvo Penadés ⁵, Jordi Antón ⁶, Francisco Ávila-Zapata ⁷, Rubèn J Cuttica ⁸, Gerd Horneff ⁹, Robert Wong ¹⁰, Mehmooda Shaikh ¹¹, Johanna Mora ¹¹, Marleen Nys ¹², Daniel J. Lovell ¹³, Alberto Martini ¹⁴ and Nicolino Ruperto ¹⁵, ¹Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, ³Panorama Medical Centre, Parow, South Africa, ⁴Universidad Nacional de Tucuman and Centro Médico Privado de Reumatología, Tucuman, Argentina, ⁵Hospital Univ. La Fe, Valencia, Spain, ⁶Hospital Sant Joan de Déu, Barcelona, Spain, ⁷Star Medica Hospital, Merida, Yucatán, Mexico, ⁸Hospital General de Niños Pedro de Elizalde, Buenos Aires, Argentina, ⁹Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ¹⁰Bristol-Myers Squibb, Princeton, ¹¹Bristol-Myers Squibb, Princeton, NJ, ¹²Bristol-Myers Squibb, Braine L’Alleud, Belgium, ¹³Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, ¹⁴IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy, ¹⁵Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy
Background/Purpose: Patients (pts) with polyarticular-course JIA (pJIA) may develop anti-drug antibodies (ADAs) in response to biologics.1 Presence of ADAs has been associated with treatment (tmt)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].